Canada’s Drug Agency has reversed its initial stance, now recommending that public drug plans provide coverage for the Alzheimer’s medication lecanemab, provided specific clinical and safety conditions are met. The Canadian Drug Expert Committee (CDEC) updated its recommendation on Thursday, citing new evidence and a pressing clinical need, despite lingering concerns over the drug’s high cost and the logistical challenges of monitoring patients.
Conditional Approval and Clinical Eligibility
The CDEC’s revised recommendation establishes strict boundaries for who can access the treatment, marketed as Leqembi. To qualify for public reimbursement, patients must be 50 years of age or older with a confirmed diagnosis of mild cognitive impairment or mild dementia caused by Alzheimer’s disease. Crucially, the committee has excluded patients who are homozygous for the APOE4 gene variant, as these individuals face the highest genetic risk for late-onset Alzheimer’s.
Treatment is not a one-time process. The agency stipulates that reimbursement must be re-evaluated after the initial six months of intravenous infusions. Continued coverage depends on clear evidence of clinical benefit and the successful completion of required MRI monitoring to detect potential side effects, such as brain swelling or microbleeding.
Did you know?
Dementia affects an estimated 772,000 Canadians today. With the country’s aging population, that figure is projected to more than double by the year 2050.
Addressing the Cost and Logistical Barriers
While the CDEC’s recommendation is a major step toward patient access, significant hurdles remain. The drug currently carries a price tag of approximately $30,000 per year for an average patient. The committee explicitly noted that this price must be “significantly reduced” before widespread public funding can be considered viable.
The recommendation now moves to the pan-Canadian Pharmaceutical Alliance (pCPA). This body, which represents federal, provincial, and territorial drug plans, is expected to initiate confidential price negotiations with the manufacturer, Eisai Co., Ltd. Additionally, the committee highlighted systemic infrastructure issues, specifically noting that “MRI capacity constraints” in various provinces could hinder the frequent monitoring required to keep patients safe during treatment.
Comparison: Lecanemab vs. Emerging Treatments
Lecanemab is not the only new arrival in the Alzheimer’s space. In May, Health Canada also approved donanemab, another drug designed to target the underlying causes of the disease rather than just managing symptoms. While lecanemab is currently in the spotlight for its revised reimbursement path, the status of public coverage for donanemab remains uncertain, as it is still under review by the Canadian Drug Agency.
Both medications function by slowing cognitive decline, allowing patients to remain in the milder stages of the disease for longer. Neither drug is considered a cure, and both require careful clinical oversight to manage potential side effects.
Pro Tip: Understanding the Clinical Process
Patients and families should consult with their neurologists regarding the specific infusion schedule. Lecanemab is administered via intravenous infusion twice monthly. Because the drug is only effective for those in early stages, timely diagnosis is essential for meeting eligibility criteria.
Frequently Asked Questions
Is lecanemab a cure for Alzheimer’s disease?
No. According to the Canadian Drug Agency, lecanemab is not a cure. It is a disease-modifying medication designed to slow cognitive decline, helping patients maintain their current level of function for a longer period.
Who is eligible for the drug under the new recommendation?
Eligibility is restricted to adults aged 50 and older with mild cognitive impairment or mild dementia due to Alzheimer’s. Patients who are homozygous for the APOE4 gene variant are excluded from the current recommendation.
What are the safety concerns associated with lecanemab?
The CDEC identified rare but serious side effects, including brain swelling and microbleeding. These require regular MRI scans, which the committee notes currently face capacity constraints across several Canadian provinces.
What happens next for public funding?
The CDEC’s recommendation is non-binding. If finalized, it will trigger price negotiations between the pan-Canadian Pharmaceutical Alliance and the manufacturer, Eisai Co., Ltd., to lower the current $30,000 annual cost.
Have questions about how these changes might impact your local health region? Subscribe to our newsletter for the latest updates on healthcare policy and medical advancements in Canada.
